Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OPTIZIOME P³ HYDROLYZER - WHEY is a proprietary nutritional supplement ingredient developed by BIO-CAT, Inc. It consists of a blend of three microbial protease enzymes (providing 50,000 HUT of fungal proteolytic activity per 250 mg dose) combined with whey protein concentrate. The product is designed to optimize protein digestion by accelerating the breakdown of proteins into absorbable amino acids. Clinical data indicates that co-ingestion with whey protein increases the bioavailability of essential amino acids (EAAs) by 14% and branched-chain amino acids (BCAAs) by 15%. Additionally, it has been shown to influence appetite regulation by reducing ghrelin levels and increasing satiety. It is marketed for use in sports nutrition, healthy aging, and for individuals on GLP-1 medications or recovering from surgery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on OPTIZIOME P³ HYDROLYZER - WHEY.